Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced it has entered into a distribution services agreement with McKesson (MCK). Under the agreement, McKesson will serve as an authorized distributor of record for LYMPHIR, or denileukin diftitox-cxdl, a novel immunotherapy approved by the FDA for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma, or CTCL, after at least one prior systemic therapy. The agreement with McKesson completes Citius Oncology’s core U.S. distribution network for LYMPHIR, which now includes all three of the largest pharmaceutical distributors in the country. This strategic milestone ensures broad and reliable access to the therapy in preparation for its planned commercial launch in the Q4.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTOR:
- Strategic Positioning and Market Potential Drive Buy Rating for Citius Oncology’s Lymphir
- Citius Oncology signs exclusive commercialization agreement with EVERSANA
- Citius Oncology’s Strategic Expansion and Market Positioning Drive Buy Rating
- Citius Oncology signs distribution agreement for Lymphir in Southern Europe
- Maxim upgrades Citius Oncology to Buy, sees its capital needs being met